Therapeutic proline derivatives
    33.
    发明授权
    Therapeutic proline derivatives 失效
    治疗脯氨酸衍生物

    公开(公告)号:US07659305B2

    公开(公告)日:2010-02-09

    申请号:US10698354

    申请日:2003-10-30

    IPC分类号: A61K31/40 A01N43/36

    摘要: The compounds of formula (I) or a pharmaceutically acceptable salt, solvate or pro-drug thereof, are proline derivatives useful in the treatment of epilepsy, faintness attacks, hypokinesia, cranial disorders, neurodegenerative disorders, depression, anxiety, panic, pain, fibromyalgia, arthritis, neuropathalogical disorders, sleep disorders, visceral pain disorders and gastrointestinal disorders. Processes for the preparation of the final products and intermediates useful in the process are included. Pharmaceutical compositions containing one or more of the compounds are also included.

    摘要翻译: 式(I)化合物或其药学上可接受的盐,溶剂化物或前体药物是用于治疗癫痫,眩晕发作,运动功能减退,颅内疾病,神经变性疾病,抑郁症,焦虑症,恐慌症,疼痛,纤维肌痛的脯氨酸衍生物 ,关节炎,神经病学障碍,睡眠障碍,内脏疼痛障碍和胃肠道疾病。 包括用于制备在该方法中有用的最终产物和中间体的方法。 还包括含有一种或多种化合物的药物组合物。

    Therapeutic use of aryl amino acid derivatives
    36.
    发明授权
    Therapeutic use of aryl amino acid derivatives 失效
    芳基氨基酸衍生物的治疗用途

    公开(公告)号:US07053122B2

    公开(公告)日:2006-05-30

    申请号:US10636406

    申请日:2003-08-07

    摘要: The compounds of formula (I) are useful in the treatment of faintness attacks, hypokinesia, cranial disorders, neurodegenerative disorders, depression, anxiety, panic, neuropathic pain, neuropathological disorders and sleep disorders. Processes for the preparation of the final products and intermediates useful in the process are included. Pharmaceutical compositions containing one or more of the compounds are also included.

    摘要翻译: 式(I)化合物可用于治疗微弱发作,运动功能减退,颅内疾病,神经变性疾病,抑郁症,焦虑症,恐慌症,神经性疼痛,神经病理学障碍和睡眠障碍。 包括用于制备在该方法中有用的最终产物和中间体的方法。 还包括含有一种或多种化合物的药物组合物。

    Pharmaceutically active compounds
    40.
    发明授权

    公开(公告)号:US06593332B2

    公开(公告)日:2003-07-15

    申请号:US10189655

    申请日:2002-07-03

    IPC分类号: A61K3152

    CPC分类号: C07D473/30

    摘要: There is provided compounds of formula IA and of formula IB, wherein R1, R2, R3, Het1 and X have meanings given in the description, which are useful in the curative and prophylactic treatment of medical conditions for which inhibition of a cyclic guanosine 3′,5′-monophosphate phosphodiesterase (e.g. cGMP PDE5) is desired.